Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 7, 2025

Vinculin Antibody

RRID:AB_10559207
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4650, RRID:AB_10559207)

Antibody Information

URL: http://antibodyregistry.org/AB_10559207

Proper Citation: (Cell Signaling Technology Cat# 4650, RRID:AB_10559207)

Target Antigen: Vinculin

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: Vinculin Antibody

Description: This polyclonal targets Vinculin

Target Organism: dg, rat, h, canine, m, mouse, r, non-human primate, human, mk

Antibody ID: AB_10559207

Vendor: Cell Signaling Technology

Catalog Number: 4650

Alternative Catalog Numbers: 4650S

Record Creation Time: 20231110T071844+0000

Record Last Update: 20241115T002325+0000

Ratings and Alerts

No rating or validation information has been found for Vinculin Antibody.

No alerts have been found for Vinculin Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 58 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Blawski R, et al. (2024) Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer. Cell reports, 43(5), 114174.

Fatalska A, et al. (2024) Recruitment of trimeric eIF2 by phosphatase non-catalytic subunit PPP1R15B. Molecular cell, 84(3), 506.

Brown RDR, et al. (2024) Overexpression of ORMDL3 confers sexual dimorphism in diet-induced non-alcoholic steatohepatitis. Molecular metabolism, 79, 101851.

Li GX, et al. (2024) Comprehensive proteogenomic characterization of rare kidney tumors. Cell reports. Medicine, 5(5), 101547.

Wu PY, et al. (2024) Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. iScience, 27(2), 108858.

Yu D, et al. (2024) Feedforward cysteine regulation maintains melanoma differentiation state and limits metastatic spread. Cell reports, 43(7), 114484.

Lal S, et al. (2023) Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor. Cancer research communications, 3(9), 1731.

Ausejo-Mauleon I, et al. (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer cell, 41(11), 1911.

Kenny TC, et al. (2023) Integrative genetic analysis identifies FLVCR1 as a plasma-membrane choline transporter in mammals. Cell metabolism, 35(6), 1057.

Miller AL, et al. (2023) DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Cancer research, 83(11), 1800.

Mark KG, et al. (2023) Orphan quality control shapes network dynamics and gene

expression. Cell, 186(16), 3460.

Flint AC, et al. (2023) Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(17), 3438.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell reports. Medicine, 4(4), 101007.

Barrington CL, et al. (2023) Synonymous codon usage regulates translation initiation. Cell reports, 42(12), 113413.

Mina E, et al. (2023) FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy. Cell reports. Medicine, 4(12), 101306.

Choi CHJ, et al. (2022) LRG1 is an adipokine that promotes insulin sensitivity and suppresses inflammation. eLife, 11.

Shagisultanova E, et al. (2022) Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Molecular cancer therapeutics, 21(1), 48.

McNamara MC, et al. (2022) Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. iScience, 25(11), 105458.

Chava S, et al. (2022) Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis. iScience, 25(5), 104211.

Jahid S, et al. (2022) Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. Cell reports, 39(1), 110641.